Cytek Biosciences Inc (CTKB) - Net Assets
Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has net assets worth $341.74 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($461.54 Million) and total liabilities ($119.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cytek Biosciences Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $341.74 Million |
| % of Total Assets | 74.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | -15.7% |
| 10-Year Change | N/A |
| Growth Volatility | 7.22 |
Cytek Biosciences Inc - Net Assets Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Cytek Biosciences Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Cytek Biosciences Inc (2019–2025)
The table below shows the annual net assets of Cytek Biosciences Inc from 2019 to 2025. For live valuation and market cap data, see Cytek Biosciences Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $341.74 Million | -13.64% |
| 2024-12-31 | $395.74 Million | +0.68% |
| 2023-12-31 | $393.06 Million | -7.63% |
| 2022-12-31 | $425.55 Million | +4.97% |
| 2021-12-31 | $405.38 Million | +2629.23% |
| 2020-12-31 | $-16.03 Million | +61.56% |
| 2019-12-31 | $-41.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cytek Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5972000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $129.00K | 0.04% |
| Other Comprehensive Income | $2.24 Million | 0.66% |
| Other Components | $441.11 Million | 129.08% |
| Total Equity | $341.74 Million | 100.00% |
Cytek Biosciences Inc Competitors by Market Cap
The table below lists competitors of Cytek Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Comintel Corporation Berhad
KLSE:7195
|
$542.52 Million |
|
Tyntek Corp
TW:2426
|
$542.70 Million |
|
CARE Ratings Limited
NSE:CARERATING
|
$542.76 Million |
|
Gansu Yatai Industrial Development Co Ltd
SHE:000691
|
$542.82 Million |
|
Canadian Tire Corporation Limited
TO:CTC
|
$542.33 Million |
|
Nextdoor Holdings Inc
NYSE:KIND
|
$542.17 Million |
|
Guangdong Songyang Recycle Resources Co Ltd
SHG:603863
|
$542.04 Million |
|
SIS LIMITED
NSE:SIS
|
$541.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytek Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 395,737,000 to 341,739,000, a change of -53,998,000 (-13.6%).
- Net loss of 66,539,000 reduced equity.
- Share repurchases of 15,074,000 reduced equity.
- Other comprehensive income increased equity by 2,225,000.
- Other factors increased equity by 25,390,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-66.54 Million | -19.47% |
| Share Repurchases | $15.07 Million | -4.41% |
| Other Comprehensive Income | $2.23 Million | +0.65% |
| Other Changes | $25.39 Million | +7.43% |
| Total Change | $- | -13.64% |
Book Value vs Market Value Analysis
This analysis compares Cytek Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.31 | $4.62 | x |
| 2020-12-31 | $-0.12 | $4.62 | x |
| 2021-12-31 | $3.03 | $4.62 | x |
| 2022-12-31 | $3.07 | $4.62 | x |
| 2023-12-31 | $2.91 | $4.62 | x |
| 2024-12-31 | $3.03 | $4.62 | x |
| 2025-12-31 | $2.68 | $4.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytek Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.02%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.35x
- Recent ROE (-19.47%) is below the historical average (-3.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -29.07% | 0.82x | 0.00x | $-12.66 Million |
| 2020 | 0.00% | 20.91% | 0.42x | 0.00x | $21.01 Million |
| 2021 | 0.74% | 2.35% | 0.28x | 1.14x | $-37.50 Million |
| 2022 | 0.61% | 1.57% | 0.32x | 1.22x | $-39.95 Million |
| 2023 | -3.09% | -6.29% | 0.39x | 1.26x | $-51.45 Million |
| 2024 | -1.52% | -3.00% | 0.40x | 1.26x | $-45.59 Million |
| 2025 | -19.47% | -33.02% | 0.44x | 1.35x | $-100.71 Million |
Industry Comparison
This section compares Cytek Biosciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytek Biosciences Inc (CTKB) | $341.74 Million | 0.00% | 0.35x | $542.48 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more